Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 103Lung Neoplasms 49Ovarian Neoplasms 44Breast Neoplasms 31Small Cell Lung Carcinoma 25Neoplasms 20Fallopian Tube Neoplasms 16Triple Negative Breast Neoplasms 14Carcinoma, Ovarian Epithelial 14Neoplasm Metastasis 12Adenocarcinoma of Lung 11Uterine Cervical Neoplasms 9Squamous Cell Carcinoma of Head and Neck 8Lymphoma, Large B-Cell, Diffuse 8Lymphoma, Non-Hodgkin 7Lymphoma 7Head and Neck Neoplasms 7Carcinoma 7Urinary Bladder Neoplasms 6Esophageal Neoplasms 6Endometrial Neoplasms 6Brain Neoplasms 6Thoracic Neoplasms 5Prostatic Neoplasms 5Melanoma 5Lung Diseases 5Adenocarcinoma Of Esophagus 5Adenocarcinoma 5Respiratory Tract Neoplasms 4Recurrence 4

Interventions

rucaparib 1Docetaxel 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × ATM Gene Mutation × Carboplatin × Clear all
NCT03442556 2025-06-12

Docetaxel, Carboplatin, and Rucaparib Camsylate in Treating Patients With Metastatic Castration Resistant Prostate Cancer With Homologous Recombination DNA Repair Deficiency

University of Washington

Phase 2 Terminated
18 enrolled
Genitourinary

ATM Gene Mutation

Data powered by HemOnc (CC BY 4.0) Colophon âš¡